CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Caris Life Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Caris Life Sciences Inc
750 West John Carpenter Freeway
Suite 800
IRVING, TX  75039  United States Ticker: CAICAI
Business Summary
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes-YesYes

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Founder David D.Halbert 69 1/18/2023 1/1/2008
President DavidSpetzler 49 11/1/2016 11/1/2016
Vice Chairman of the Board, Executive Vice President Brian J.Brille 64 1/1/2018 1/1/2018
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Pharmatech, Inc. 789 Sherman St., Suite 310 Denver CO United States

Business Names
Business Name
CAI
Caris MPI, Inc.
Caris Science, Inc. Texas
Cohen Dermatopathology
Pathology Partners Inc.
Pharmatech, Inc.

General Information
Outstanding Shares: 277,932,779 (As of 6/18/2025)
Stock Exchange: NASD
Federal Tax Id: 852077369


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 5, 2025